Remedium Capital Partners, LLC 13F Holdings · Q2 2026
Remedium Capital Partners, LLC reported 6 securities worth $451.63M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ORKA (32.99%), SYRE (28.78%), APGE (17.24%). Among its top 25 positions this quarter: 1 new, 2 added, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | $149.0M | 32.99% | 1.6M | Hold |
| 2 | SYRE | Spyre Therapeutics Inc | $130.0M | 28.78% | 1.5M | Added |
| 3 | APGE | Apogee Therapeutics Inc | $77.9M | 17.24% | 586,691 | Added |
| 4 | DMRA | Damora Therapeutics Inc | $53.2M | 11.78% | 2.0M | Hold |
| 5 | JBIO | Jade Biosciences Inc | $35.1M | 7.76% | 1.6M | Hold |
| 6 | CBIO | Crescent Biopharma Inc | $6.5M | 1.44% | 361,250 | New |
| 7 | CBIO | Crescent Biopharma Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR